Bristol-Myers Squibb
Checkpoint inhibitor patent challenges are settled by AZ and BMS
SG Tylor
AstraZeneca has announced the resolution of three lawsuits filed against it by Bristol-Myers Squibb (BMS) and Ono Pharma, alleging patent ...
Bristol Myers lowers the company’s 2023 revenue forecast for Revlimid by $1 billion
SG Tylor
Bristol Myers Squibb (BMS) had a promising long-term outlook after securing FDA approvals for three drugs with peak sales potential ...
In unresectable/metastatic urothelial carcinoma, upfront nivolumab/chemotherapy prolongs survival
SG Tylor
Source –Bristol-Myers Squibb Nivolumab plus chemotherapy showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival ...
BMS purchases the Prothena Alzheimer’s medication in a $2.2 billion transaction
SG Tylor
Source: Prothena Bristol-Myers Squibb has taken an option on a tau protein-targeting antibody in early-stage clinical development from Prothena on ...
